Trial Profile

A phase 1b study assessing efficacy, safety and tolerability of COR388 in treatment of Alzheimer's disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atuzaginstat (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

Most Recent Events

28 Jul 2020 According to a Cortexyme media release, data are being presented at the Alzheimer's Association International Conference 2020 (AAIC).
22 Jul 2020 According to a Cortexyme media release, results of an analysis using data from this trial will be presented at the Alzheimers Association International Conference 2020 (AAIC). The largest international meeting dedicated to advancing dementia science, AAIC will be held as a virtual event this year from July 27-31, 2020.
20 May 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com